



Institute of Cell Biology and Immunology University of Stuttgart

6th Symposium on molecular mechanisms and therapeutic
approaches in cancer research

2011, April 4th — 6th, Freudenstadt-Lauterbad

Monday, April 4th

1. Cancer immunotherapy: Immunostimulatory antibody fusion proteins

12:30 **Introduction** Dr. Dafne Müller

12:35 **Antibody IL-15 fusionproteins for cancer immunotherapy** Vanessa Kermer

12:55 **Costimulatory antibody fusionproteins for tumor immunotherapy** Nora Hornig

2. TNF signal transduction — mathematical modelling

13:15 **Understanding apoptosis on a quantitative basis** Prof. Dr. Peter Scheurich

13:25 **Death ligand meets receptor — molecular interactions in signal complex formation** Simon Neumann

13:50 **Response of cancer-associated fibroblasts to anti-cancer treatment in monoculture and tissue culture** Silke Haubeiß

Statistics in GraphPad Prism

14:15 **Lagemaß- und Mittelwertvergleiche** Dipl.-Ing. Boris Kulig

15:00 Coffee break

15:30 **Anwendung der nicht-linearen Regression am Beispiel einer Dose-Response-Kurve** Dipl.-Ing. Boris Kulig

3. Physiological functions of START domain proteins: From lipid transfer to tumor suppression

16:15 **Introduction** Dr. Monilola Olayioye

16:25 **An essential role for the RhoGAP protein DLC3 in adherens junction integrity** Anja Braun

16:50 **DLC1 in breast epithelial differentiation and cellular transformation** Annabell Bischoff

17:15 **How membrane lipid composition controls growth factor signaling and cell motility — Implications for cell transformation** Dr. Nicole Weis

17:45 Dinner

4. Poster session I

19:30 Ellen Brenner | Stephan Eisler | Bettina Huck | Jan Körner | Olaf Maier | Simon Neumann | Heike Niessner

Tuesday, April 5th

5. Biomedical engineering - targeted therapeutics for solid tumors

- 8:30 **Introduction** Prof. Dr. Roland Kontermann
- 8:40 **In vitro characterization of Atrosab, a humanized antagonistic anti-TNF receptor one-specific antibody** Fabian Richter
- 9:05 **Biomarker discovery and analysis of signal transduction pathways in breast cancer** Johanna Sonntag
- 9:30 **Pharmacokinetics of small recombinant antibody molecules** Aline Schwarz
- 9:55 **TRAIL-coupled immunoliposomes** Oliver Seifert

10:15 Coffee break

6. Molecular mechanisms of UVB-induced signal transduction and apoptosis

- 10:45 **Cell death or cell survival?!** Dr. Dagmar Kulms
- 10:55 **Progress in 3D melanoma treatment** Hanna Vörsmann
- 11:20 **Seeing cell death from different angles** Ines Müller
- 11:50 **Metastatic melanoma cells are sensitive to drugs inducing endoplasmic reticulum stress mediated apoptosis** Daniela Beck

12:15 Lunch

7. Establishing of monoclonal antibodies, recombinant enzymes and cytokine receptor derivatives

- 13:45 **Development of optimized techniques and materials to produce and purify polymer modified proteins** Dr. Heiner Böttinger
- 13:55 **Aldehyde PEGylation kinetics** Anna Moosmann

btS – eine Studenteninitiative stellt sich vor

- 14:15 Bettina Huck

15:00 Cultural event

8. Poster session II

- 17:30 Dr. Sandra Barisic | Philipp Diebolder | Roman Fischer | Manuela Hörnle | Robert Lindner | Michaela Strotbek

19:00 Dinner

Wednesday, April 6th

9. Molecular characterization and in vivo function of protein kinase D (PKD)

- 9:00 **Protein kinase D signaling: Secretion, migration and beyond** Dr. Angelika Haußer
- 9:15 **Role of PKD in Golgi mitotic checkpoint control** Christine Kienzle
- 9:40 **PKD controls insulin secretion in beta cells** Dr. Kornelia Ellwanger
- 10:10 **PKD is a critical regulator of osteogenic differentiation** Dr. Nina Konjer

10:40 Coffee break

10. Engineering death receptor ligands for cancer therapy

- 11:15 **Introduction** Prof. Dr. Klaus Pfizenmaier
- 11:25 **Novel EGFR-specific scTRAIL constructs with enhanced biological activity** Dr. Martin Siegemund

12:00 Voting for best posters and talks

12:30 Lunch

Awards for best posters and talks



Poster Session I

TLR-mediated inflammation promotes seeding of B16-melanoma metastases Ellen Brenner

Global analysis of Protein kinase D targets by a SILAC-based screen Stephan Eisler

Regulation of the ArfGAP protein GIT1 by a PKD3-mediated phosphorylation on serine 46 Bettina Huck

Target identification in pancreatic neuroendocrine tumors Jan Körner

Modulation of TNF Signaling Pathways as a Potential Therapy for Multiple Sclerosis Olaf Maier

The transmembrane domains of TRAILR1 and TRAILR2 regulate the distinct signalling characteristics of the receptors Simon Neumann

Inhibition of the PI3K-AKT signaling pathway to overcome therapy resistance in melanoma-derived brain metastasis Heike Niessner

Poster Session II

PKD-regulated ECM degradation monitored by an optical biosensor Dr. Sandra Barisic

Therapeutic antibodies from tumor patient libraries using phage display Philipp Diebolder

A Soluble TNF Receptor 2 Agonist to Treat Neurodegenerative Diseases Roman Fischer

Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis Manuela Hörnle

Development of a prokaryotic production and purification strategy for anti-EGFR scFv Robert Lindner

A miRNA library screen to improve productivity of CHO cells Michaela Strotbek

Chairpersons

1. Christine Kienzle | Hanna Vörsmann
2. Fabian Richter | Michaela Strotbek
3. Roman Fischer | Olaf Maier
4. Dr. Angelika Haußer | Dr. Monilola Olayioye
5. Stefan Eisler | Dr. Nina Konjer
6. Robert Lindner | Martin Siegemund
7. Dr. Kornelia Ellwanger
8. Dr. Dagmar Kulms | Dr. Dafne Müller
9. Annabell Bischoff | Bettina Huck
10. Dr. Sandra Barisic

biomolecules



Win Your Favorite Antibody at the IZI PhD Retreat 2011!

Complete a Raffle Ticket for a Chance to Win a Free Sigma® Antibody!

Visit Our Booth and Receive 25% Off Your Next Antibody Order

Venue Tagungszentrum der Universität Stuttgart

Date Monday, April 4, 2011

Time 12:00 - 20:00

Sigma Antibodies – Unmatched Scope, Content and Quality:

- 40,000+ Monoclonal and polyclonal primary antibodies
- Secondary antibodies and conjugates
- WB, IHC, IF, ELISA, ChIP, and more
- Backed by the Antibody Bioguarantee Program – if our antibody does not perform in your application, we will issue a full credit or replacement

wherebiobegins.com/antibodyexplorer



Bioguarantee
Antibodies

Sigma Life Science ensures you'll always have the highest caliber tools to advance your research.

Bioguarantee Guidelines: Experimental results must be submitted via the Antibody Bioguarantee Form within 12 weeks of the date of purchase. All required fields of the Antibody Bioguarantee Form must be completed. Refunds and replacements contingent to claim review by technical service team. Credit covers the cost of antibody. Product replacements depend on product availability.

For Bioguarantee details, visit
wherebiobegins.com/bioguarantee

For more information, contact:
Dr. Jana Wünschmann
Sales Specialist Biotech
+49 (0) 172 861 5003
jana.wuenschmann@sial.com

Sigma and Sigma-Aldrich are registered trademarks of Sigma-Aldrich Biotechnology, LP and Sigma-Aldrich Co.

SIGMA-ALDRICH

MSK_EMEA
30350
1021

SIGMA Where *bio* begins™
Life Science